Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9684492 | 0.95 | KCNH3 (0.62) | KCNH3SMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL10825975 | 0.83 | KCNH3 (0.50) | KCNH3SMN1; SMN2ALDH1A1HPGDGAA | |
| Hydrochloric Acid SCHEMBL10986438 | 0.81 | KCNH3 (0.52) | KCNH3SMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL29204233 | 0.79 | EGLN2 (0.57) | KCNH3SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL175818 | 0.79 | NPC1 (0.56) | KCNH3SMN1; SMN2ALDH1A1MAPTTDP1 | |
| SCHEMBL18901390 | 0.79 | KCNH3 (0.50) | KCNH3SMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL2392508 | 0.78 | KCNH3 (0.46) | KCNH3SMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL19392469 | 0.78 | HPGD (0.58) | KCNH3SMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL20490286 | 0.78 | HPGD (0.54) | KCNH3SMN1; SMN2ALDH1A1HPGDGAA | |
| SCHEMBL1962657 | 0.77 | KCNH3 (0.55) | KCNH3SMN1; SMN2ALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675809-B1 | USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3675809-B1 | USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2023-09-27 | — | — | EP | disclosed |
| CN-111343963-B | Use of physiologically cooling active ingredients and compositions comprising such active ingredients | 巴斯夫欧洲公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11434220-B2 | Use of physiological cooling active ingredients, and compositions comprising such active ingredients | BASF SE (DE) | 2022-09-06 | — | — | US | disclosed |
| US-20200190052-A1 | USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20200190052-A1 | USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2020-06-18 | — | — | US | disclosed |
| WO-2019043164-A1 | USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENTS | BASF SE (DE) | 2019-03-07 | — | — | WO | disclosed |
| US-8586617-B2 | Aminomethyl-4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2076497-B1 | AMINOMETHYL-4-IMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110086860-A1 | COMPOUND | KIMURA TEIJI | 2011-04-14 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| EP-2076497-A1 | AMINOMETHYL-4-IMIDAZOLES | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | disclosed |
| WO-2008046757-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
| EP-1417196-A1 | DNA-PK INHIBITORS | Cancer Research Technology Limited (GB) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003024949-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
| US-5162322-A | Anxiolytic agetns; humans, animals | A. H. ROBBINS COMPANY, INCORPORATED (US) | 1992-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086860-A1 | COMPOUND | ARRB1, NR3C2, ADRA2C | KCNH3 600/4885SMN1; SMN2 1928/4885ALDH1A1 149/4885 |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | KCNH3 3935/4885SMN1; SMN2 82/4885ALDH1A1 451/4885 |
| US-11434220-B2 | Use of physiological cooling active ingredients, and compositions comprising such active ingredients | TRPM8, TRPM7, TRPM5 | KCNH3 491/4885SMN1; SMN2 4063/4885ALDH1A1 1810/4885 |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | INMT, HTR4, MC4R | KCNH3 751/4885SMN1; SMN2 1921/4885ALDH1A1 631/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | KCNH3 659/4885SMN1; SMN2 2370/4885ALDH1A1 58/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | KCNH3 1859/4885SMN1; SMN2 235/4885ALDH1A1 1375/4885 |
| US-20200190052-A1 | USE OF PHYSIOLOGICAL COOLING ACTIVE INGREDIENTS, AND COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENTS | TRPM8, TRPM7, TRPM5 | KCNH3 491/4885SMN1; SMN2 4063/4885ALDH1A1 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.